甲状腺结节不典型细针抽吸细胞学检查中 ThyroSeq v3 基因组分类器的临床验证。
Clinical validation of the ThyroSeq v3 genomic classifier in thyroid nodules with indeterminate FNA cytology.
机构信息
Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania.
出版信息
Cancer Cytopathol. 2019 Apr;127(4):225-230. doi: 10.1002/cncy.22112. Epub 2019 Feb 27.
Abstract
Molecular testing of thyroid fine‐needle aspiration specimens has been developed with the primary goals of resolving the uncertainty of indeterminate cytology and avoiding the diagnostic surgeries generally recommended for these patients. A recent prospective, double‐blinded, multicenter study reported the results of the clinical validation of the ThyroSeq v3 genomic classifier in thyroid nodules with indeterminate fine‐needle aspiration cytology.
摘要
甲状腺细针抽吸标本的分子检测已经发展起来，其主要目标是解决不确定的细胞学的不确定性，并避免对这些患者通常推荐的诊断性手术。最近一项前瞻性、双盲、多中心研究报告了 ThyroSeq v3 基因组分类器在具有不确定细针抽吸细胞学的甲状腺结节中的临床验证结果。
相似文献
1
Clinical validation of the ThyroSeq v3 genomic classifier in thyroid nodules with indeterminate FNA cytology.
Cancer Cytopathol. 2019 Apr;127(4):225-230. doi: 10.1002/cncy.22112. Epub 2019 Feb 27.
2
Thyroid cytology smear slides: An untapped resource for ThyroSeq testing.
Cancer Cytopathol. 2021 Jan;129(1):33-42. doi: 10.1002/cncy.22331. Epub 2020 Jul 22.
3
Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules.
Cancer. 2018 Apr 15;124(8):1682-1690. doi: 10.1002/cncr.31245. Epub 2018 Jan 18.
4
Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.
JAMA Oncol. 2019 Feb 1;5(2):204-212. doi: 10.1001/jamaoncol.2018.4616.
5
The role of ThyroSeq V3 testing in the management of patients with indeterminate thyroid nodules on fine needle aspiration.
Diagn Cytopathol. 2021 Jul;49(7):838-841. doi: 10.1002/dc.24751. Epub 2021 Apr 17.
6
Benign call rate and molecular test result distribution of ThyroSeq v3.
Cancer Cytopathol. 2019 Mar;127(3):161-168. doi: 10.1002/cncy.22088. Epub 2018 Dec 18.
7
Evaluation of 167 Gene Expression Classifier (GEC) and ThyroSeq v2 Diagnostic Accuracy in the Preoperative Assessment of Indeterminate Thyroid Nodules: Bivariate/HROC Meta-analysis.
Endocr Pathol. 2019 Mar;30(1):8-15. doi: 10.1007/s12022-018-9560-5.
8
Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
Del Med J. 2016 Dec;88(12):366-372.
9
The Role of the ThyroSeq v3 Molecular Test in the Surgical Management of Thyroid Nodules in the Canadian Public Health Care Setting.
Thyroid. 2020 Sep;30(9):1280-1287. doi: 10.1089/thy.2019.0539. Epub 2020 May 5.
10
Role of Ancillary Techniques in Thyroid Cytology Specimens.
Acta Cytol. 2020;64(1-2):40-51. doi: 10.1159/000496502. Epub 2019 Apr 4.
引用本文的文献
1
High Allele Frequency Signals Increased Risk of Promoter Mutations in Thyroid Tumors.
Cancers (Basel). 2025 Aug 30;17(17):2851. doi: 10.3390/cancers17172851.
2
Role of Publicly-Funded Molecular Testing in Surgical Management of Thyroid Nodules within Canadian Medicare: Clinical Assessment of ThyroSeqv3 Molecular Test Pilot Project at McGill University.
J Otolaryngol Head Neck Surg. 2025 Jan-Dec;54:19160216251336687. doi: 10.1177/19160216251336687. Epub 2025 May 28.
3
Description of a New miRNA Signature for the Surgical Management of Thyroid Nodules.
Cancers (Basel). 2024 Dec 18;16(24):4214. doi: 10.3390/cancers16244214.
4
Performance of the AmpliSeq NGS panel in thyroid nodules with indeterminate cytology.
Eur Thyroid J. 2025 Jan 21;14(1). doi: 10.1530/ETJ-24-0160. Print 2025 Feb 1.
5
Molecular Markers in Follicular and Oncocytic Thyroid Carcinomas: Clinical Application of Molecular Genetic Testing.
Curr Oncol. 2024 Oct 1;31(10):5919-5928. doi: 10.3390/curroncol31100441.
6
Small Multi-Gene DNA Panel Can Aid in Reducing the Surgical Resection Rate and Predicting the Malignancy Risk of Thyroid Nodules.
Endocrinol Metab (Seoul). 2024 Oct;39(5):777-792. doi: 10.3803/EnM.2024.2034. Epub 2024 Oct 14.
7
Editorial: Molecular characterization of thyroid lesions in the era of "next generation" techniques: volume II.
Front Endocrinol (Lausanne). 2024 Jul 29;15:1460239. doi: 10.3389/fendo.2024.1460239. eCollection 2024.
8
: A Novel Receptor Tyrosine Kinase Fusion Oncogene in Pediatric Thyroid Cancer.
Thyroid. 2024 Oct;34(10):1308-1313. doi: 10.1089/thy.2024.0224. Epub 2024 Aug 27.
9
Does the likelihood of malignancy in thyroid nodules with RAS mutations increase in direct proportion with the allele frequency percentage?
J Otolaryngol Head Neck Surg. 2023 Feb 11;52(1):12. doi: 10.1186/s40463-022-00611-8.
10
Coexisting Molecular Alterations Increase the Risk of Malignancy in Thyroid Nodules with Copy Number Alterations.
Cancers (Basel). 2022 Dec 13;14(24):6149. doi: 10.3390/cancers14246149.
本文引用的文献
1
Benign call rate and molecular test result distribution of ThyroSeq v3.
Cancer Cytopathol. 2019 Mar;127(3):161-168. doi: 10.1002/cncy.22088. Epub 2018 Dec 18.
2
Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.
JAMA Oncol. 2019 Feb 1;5(2):204-212. doi: 10.1001/jamaoncol.2018.4616.
3
Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes.
Cancer Cell. 2018 Aug 13;34(2):256-270.e5. doi: 10.1016/j.ccell.2018.07.002.
4
Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell Carcinoma.
Cancer Cell. 2018 Aug 13;34(2):242-255.e5. doi: 10.1016/j.ccell.2018.06.013.
5
Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules.
JAMA Surg. 2018 Sep 1;153(9):817-824. doi: 10.1001/jamasurg.2018.1153.
6
The Diagnosis and Management of Thyroid Nodules: A Review.
JAMA. 2018 Mar 6;319(9):914-924. doi: 10.1001/jama.2018.0898.
7
Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules.
Cancer. 2018 Apr 15;124(8):1682-1690. doi: 10.1002/cncr.31245. Epub 2018 Jan 18.
8
Distinguishing parathyroid and thyroid lesions on ultrasound-guided fine-needle aspiration: A correlation of clinical data, ancillary studies, and molecular analysis.
Cancer Cytopathol. 2017 Sep;125(9):674-682. doi: 10.1002/cncy.21888. Epub 2017 Jun 16.
9
American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features.
Thyroid. 2017 Apr;27(4):481-483. doi: 10.1089/thy.2016.0628. Epub 2017 Feb 21.
10
Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): A changing paradigm in thyroid surgical pathology and implications for thyroid cytopathology.
Cancer Cytopathol. 2016 Sep;124(9):616-20. doi: 10.1002/cncy.21744. Epub 2016 May 20.
Zotero 插件